Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA

Archives of Facial Plastic Surgery

Volumn 14, Issue 3, 2012, Pages 198-204

  Yu, Kenneth C Y ^a,b   Nettar, Kartik D ^a,b   Bapna, Sumit ^a,b   Boscardin, W John ^b   Maas, Corey S ^a,b  

^a Maas Clinic   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTHETIC SURGERY; EYE; FEMALE; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHOTOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; DOUBLE-BLIND METHOD; EYE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PHOTOGRAPHY; PROSPECTIVE STUDIES; SKIN AGING; TIME FACTORS;

EID: 84863916367     PISSN: 15212491     EISSN: 15383660     Source Type: Journal    
DOI: 10.1001/archfacial.2011.1142     Document Type: Article

References (24)

1. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope. 2001;111(2):218-226. (Pubitemid 32142827)
2. Ramirez AL, Reeck J, Maas CS. Preliminary experience with botulinum toxin type B in hyperkinetic facial lines. Plast Reconstr Surg. 2002;109(6):2154- 2155. (Pubitemid 34492457)
3. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 2002;126 (5):459-467. (Pubitemid 41123531)
4. Ascher B, Klap P, Marion MH, Chanteloub F. Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles: an initial study. Ann Chir Plast Esthet. 1995;40(1):67-76.
5. Ascher B. Facial rejuvenation by non-endoscopic lifting and botulinum toxin injection. Cah Opthalmol. 2000;45:25-31.
6. Olver JM. Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. BMJ. 1998;82:528-533. (Pubitemid 28266425)
7. Erian A, Ionescu NE. Combination treatment of glabellar rhytids. Int J Cosmetic Surg. 1999;7(1):14-17.
8. Feller G, Bayerl C, Jung E, Rzany B. Treatment of dynamic facial wrinkles with botulinum toxin type A (Dysport)-a pilot study. Akt Dermatol. 2000;26:65-69. (Pubitemid 30191115)
9. Le Louarn C. Botulinum toxin and facial wrinkles: a new injection procedure. Ann Chir Plast Esthet. 1998;43(5):526-533. (Pubitemid 28548631)
10. Rubin M, Dover J, Maas C, Nestor M. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29(6)(suppl):S50-S56.
11. Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol. 2011;10(1):39-44.
12. Baumann L, Brandt FS, Kane MA, Donofrio LM. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29(6)(suppl):S57-S65.
13. Carruthers A, Carruthers J, Hardas B, et al. A validated grading scale for crow's feet. Dermatol Surg. 2008;34(suppl 2):S173-S178.
14. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, doseranging study. Dermatol Surg. 2009;35(10):1478-1486.
15. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebocontrolled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1, special issue):S51-S59. (Pubitemid 46051400)
16. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet. 1994; 344(8920):474-475.
17. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations [letter]. J R Soc Med. 1994;87(11):719. (Pubitemid 24334671)
18. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995;59(1):102-103.
19. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med. 1993;86(8):493-494. (Pubitemid 23226068)
20. Breidenbach MA, Brunger AT. New insights into clostridial neurotoxin-SNARE interactions. Trends Mol Med. 2005;11(8):377-381. (Pubitemid 41080579)
21. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon. 2009;54(5):683-689.
22. Dysport [package insert]. Wrexham, UK: Ipsen Biopharm Ltd; 2009.
23. Botox Cosmetic [package insert]. Irvine, CA: Allergan Inc; 2009.
24. Nettar KD, Yu KCY, Bapna S, Boscardin J, Maas CS. An internally controlled, doubleblind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2011;13(6):380-386. doi:10.1001/archfacial.2011.37.